RHHBF - Emerging Leaders: Roche And Viking Therapeutics In The Obesity Treatment Race
2024-05-17 14:15:51 ET
Summary
- Roche's acquisition of Carmot Therapeutics and their obesity drug CT-388 showed promising Phase 1b results, boosting Roche's stock by 4%.
- CT-388 demonstrated significant weight loss but lacked detailed safety data, making comprehensive evaluation challenging.
- Comparing Roche's and Viking's drugs reveals potential, but Viking may edge out in efficacy and safety based on current data.
- Investment recommendation: Consider both Roche and Viking for exposure to the obesity treatment market. VKTX for higher risk and potential, Roche for stability.
Roche's Big Bet on Carmot Therapeutics Starts to Weigh In
Roche Holding AG 's ( OTCQX:RHHBY ) $2.7 billion acquisition of obesity developer Carmot Therapeutics earlier this year paid dividends yesterday when the company reported Phase 1b data. The data focused on CT-388, a "once-weekly subcutaneous injectable, dual GLP-1/GIP receptor agonist being developed for the treatment of obesity and type 2 diabetes." The results boosted Roche's stock by 4%, equivalent to ~$8 billion in market capitalization....
Emerging Leaders: Roche And Viking Therapeutics In The Obesity Treatment Race